|
Clinical characteristics |
|
| Characteristics |
Value |
|
|
|
| Patients |
38 |
| Age, y |
|
| Median |
41 |
| Range |
(11–68) |
| Sex |
|
| Male |
22 |
| Female |
16 |
| Diagnosis |
|
| Acute leukemia |
16 |
| Lymphoma |
6 |
| Multiple myeloma |
4 |
| Myelodyspastic syndrome |
4 |
| Solid tumor |
4 |
| Non neoplastic disorders |
3 |
| Chronic lynphocytid leukemia |
1 |
| Acute GVHD |
|
| 0–I |
27 |
| II–IV |
11 |
| Total body irradiation |
|
| Yes |
15 |
| No |
23 |
| Conditioning regimen |
|
| Standard |
25 |
| Reduced intensity conditioning |
13 |
| Type of transplant |
|
| Related |
30 |
| Unrelated |
8 |
| Hemopoietic reconstitution |
|
| Median days of PMN >0.5 × 109/L (range) |
16 (11 – 41) |
| Median days of PLTS >20 × 109/L (range) |
15 (9 – 65) |
| Median days of PLTS >50 × 109/L (range) |
18 (11 – 88) |
| Source of stem cells |
|
| Peripheral blood |
31 |
| Bone marrow |
4 |
| Cord blood |
3 |
| Prophylaxis of aGVHD |
|
| CyA+MTX |
25 |
| CyA+MMF |
6 |
| CyA+PDN |
4 |
| Other |
3 |
| CMV status (donor/recipient) |
|
| Positive/positive |
26 |
| Negative/positive |
10 |
| Positive/negative |
2 |
| Deaths |
4 |
|
GVHD: Graft versus host disease; CyA: Cyclosporin-A; MTX: Methotrexate; PDN: Prednisone; CMV: Cytomeglovirus. MMF: Micofenolate Mofetil; PMN: Peripheral Mononuclear cells; PLTS: Platelets | |
Gentile et al. BMC Infectious Diseases 2006 6:167 doi:10.1186/1471-2334-6-167 |
|